Navigating India's Rare Disease Treatment Funding Crisis

Managing complex genetic disorders presents major challenges in clinical practice. Consequently, access to continuous rare disease treatment funding remains vital for sustaining patient health across India. The Lysosomal Storage Disorders Support Society recently petitioned the Prime Minister regarding therapy interruptions. Specifically, over 160 patients have exhausted their 50 lakh rupee grant under national rare disease policies.

Clinical Impact of Rare Disease Treatment Funding Gaps

Abrupt cessation of enzyme replacement therapy causes rapid clinical decline in pediatric patients. For instance, children diagnosed with Pompe and Gaucher disease experience organ enlargement and skeletal pain when treatment stops. Furthermore, prolonged therapy discontinuation often causes irreversible musculoskeletal complications and hematological deterioration. Many affected individuals are toddlers and young children who cannot tolerate sudden interruptions in care. Therefore, treating clinicians at designated Centres of Excellence face critical ethical and management dilemmas.

Structural Gaps in the National Policy Framework

The National Policy for Rare Diseases currently provides financial support capped at 50 lakh rupees per patient. However, chronic lysosomal storage disorders require lifelong enzyme infusions that rapidly exceed this financial cap. As a result, families exhaust their allotted funds within a few years of beginning therapy. Additionally, ongoing litigation before the Supreme Court leaves patients without a clear long-term mechanism. Advocacy groups emphasize that policy architects must establish sustainable continuity-of-treatment protocols immediately.

Proposed Interim Measures for Centres of Excellence

Patient advocacy organizations have recommended a case-by-case funding model to ensure therapeutic continuity. Moreover, they urge the health ministry to release emergency funds while judicial proceedings remain sub judice. Hospitals designated as Centres of Excellence should urgently identify and prioritize high-risk pediatric cases. Consequently, timely administrative action can prevent preventable disability and premature mortality among vulnerable populations.

Frequently Asked Questions

Q1: Why are rare disease patients facing therapy interruptions in India?

Many patients have reached the 50 lakh rupee financial assistance ceiling set under the National Policy for Rare Diseases 2021. Because conditions like Gaucher and Pompe disease require lifelong therapy, exhausting these funds halts vital drug supplies.

Q2: What clinical risks arise when enzyme replacement therapy stops abruptly?

Stopping enzyme replacement therapy triggers severe symptom recurrence, including hepatosplenomegaly, hematological crises, progressive muscle weakness, and irreversible organ damage. Consequently, affected children experience rapid health regression.

Q3: What solutions have advocacy groups proposed to address this crisis?

Advocacy societies have requested an interim financial arrangement and case-by-case funding through existing policy mechanisms. Furthermore, they demand a permanent continuity-of-treatment model so patients with lifelong disorders do not lose access to care.

References

1. Rare disease patients seek PM’s intervention to secure additional funds fortreatment - ETHealthworld
2. Press Information Bureau, Ministry of Health and Family Welfare. Details of National Policy for Rare Diseases.
3. Indian Organization for Rare Diseases. Rare Disease Treatment Amount Hiked to Rs 50 lakh, Covers All Diseases Now!